In their key experiments, they compared the effect of CLCF1 with that of sera from FSGS patients on glomerular albumin permeabilityin vitro using anti-CLCF1 antibody or inhibitors of JAK2 and STAT3. Here, JAK2 is linked to focal segmental glomerulosclerosis.